Search for Angina in Cardiology

Symptom control in patients with CAD merits more attention.
CME Exam

In a primary care setting, patients with angina alone do not necessarily fare better than those with other manifestations of ischemic heart disease.

For patients with chronic CAD, an observed advantage of early PCI over initial medical management was small and transient.
CME Exam

An analysis of registry data reveals several patient factors that should prompt heightened vigilance for angina after MI.

A focused update of the 2002 ACC/AHA guidelines amends secondary prevention recommendations.

In patients presenting to an emergency department, presence and type of symptoms did not predict inducible myocardial ischemia.

In our summary Health Status and Angina Relief Results from COURAGE, published online on August 13, 2008, we incorrectly described an initial treatment strategy . . .

Compared with medical therapy, revascularization improved some long-term outcomes in patients with stable multivessel disease.
CME Exam

More evidence that the presence of ischemic symptoms without underlying obstructive arteriostenosis warrants heightened vigilance, if not intervention

In a randomized comparison of bivalirudin and heparin, a significant reduction in bleeding events in the bivalirudin group did not translate into reductions in overall morbidity or mortality.

In a prospective study, inducible ischemia predicted adverse events better than angina symptoms did, but the evidence does not yet support a change in clinical practice.

To identify the patient characteristics most associated with quality-of-life (QOL) improvement after elective percutaneous coronary intervention (PCI), researchers studied patients without acute MI who underwent . . .

No patients with <50% stenosis experienced cardiac death or myocardial infarction within 30 days.

In pooled results from 17 randomized trials, PCI was associated with a survival advantage compared with medical therapy.
CME Exam

The 2007 guidelines emphasize early diagnosis and risk stratification to guide decisions on invasive vs. noninvasive treatment.

Derived from outpatient data in 34 European countries

A new model derived from data from the ACTION trial

New recommendations pertain mainly to platelet inhibition.

A new scoring system could facilitate clinical decision making.

Several studies have raised concerns about the safety of calcium-channel blockers (CCBs). Now, in a manufacturer-sponsored, multinational, randomized, double-blind trial, researchers have compared the long-acting . . .